$IART

Integra slips after guidance cut due to flooding (IART:NASDAQ)

Integra LifeSciences (IART) fell over 10% premarket after cutting full-year guidance below analyst estimates, attributing the reduction to a July flooding event at its Cincinnati facility. The company lowered revenue and adjusted earnings forecasts. (IART:NASDAQ)

Original reporting
Published Oct 2, 2026, 1:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 1:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefMarket movers
Primary signal
$IART
Bearish
medium confidence
Mentioned
$IART
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$IARTBearishHigh
01

Why it matters

The guidance reduction and operational disruption caused a sharp pre‑market sell‑off, highlighting supply‑chain vulnerability.

02

Market read

The news directly affects IART shareholders and may influence sentiment in the broader med‑tech sector.

03

What to watch

Potential insurance recoveries or cost‑saving measures could mitigate earnings hit.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Integra LifeSciences announced a guidance cut due to a July flooding event at its Cincinnati plant.

Company-level read

Ticker impact

$IARTBearishMedium confidence
Context

Integra LifeSciences cut full-year guidance after a flooding event at its Cincinnati facility, triggering a >10% pre‑market drop.

Expected impact

likely continued downside as investors price in reduced outlook

Evidence & confidence

Guidance cuts historically lead to sell‑offs; the flood adds operational risk.

Market effects

Medical device sector may see broader scrutiny of supply‑chain risks.

U.S. biotech stocks could face short‑term pressure.

Limited to investors with exposure to Integra and related med‑tech peers.

Counterpoint

If the flood impact is short‑lived, the stock may rebound on a valuation reset.

Key entities

  • Integra LifeSciences

    Medical device manufacturer listed on Nasdaq (IART).

Related articles

$IARTHighAI 8/10

Why is Integra LifeSciences stock tumbling today?

Integra LifeSciences (IART) shares fell 16.2% to $13.49 after lowering its 2026 revenue and EPS guidance due to flooding damage at a key facility. The company expects $7M in Q3 revenue loss and $15M-$20M in Q4. It also announced a $600M debt refinancing. The stock dropped despite a positive U.S. market day.

$IARTHighAI 8/10

Integra LifeSciences Cuts FY26 Guidance Following Cincinnati Facility Flooding; Stock Tumbles 11.4%

Integra LifeSciences (IART) cut its FY26 adjusted earnings and revenue guidance due to July flooding at its Cincinnati facility. Q3 adjusted earnings are expected between $0.55 and $0.59 per share on revenues of $410M-$412M. FY26 adjusted earnings are now projected at $2.30-$2.40 per share on revenues of $1.634B-$1.654B, down from previous guidance. The stock fell 11.44% in pre-market trading.

$IARTMed

Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance

INTEGRA LIFESCIENCES HOLDINGS CORP (IART) filed an SEC Form 8-K — Results of Operations and Financial Condition. Integra LifeSciences Integra LifeSciences Announces Preliminary Third Quarter Results and Updates Full-Year 2026 Guidance PRINCETON, N.J., October 2, 2026 – Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today provided certa

$IARTHigh

Integra LifeSciences cuts 2026 guidance after flooding impact

Integra LifeSciences (IART) lowered its 2026 guidance due to flooding at its Cincinnati facility, reducing revenue and EPS forecasts. Q3 revenue is expected at $410M-$412M, with full-year revenue now projected at $1.634B-$1.654B. The company estimates a $7M Q3 and $15M-$20M Q4 revenue impact. Full operations are expected to resume by Q2 2027, with insurance covering some losses. CEO Stuart Essig anticipates Q3 operating cash flow of over $85M and full-year cash flow of $190M-$200M.